Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: A case for further study

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 4, 2011, Pages 348-353

  Monnier, Louis ^a   Colette, Claude ^a   Michel, Françoise ^a   Cristol, Jean Paul ^a   Owens, David R ^b  

^a UNIV MONTPELLIER   (France)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Insulin doses; Oxidative stress; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 8 ISOPROSTAGLANDIN F2 ALPHA; CHOLESTEROL; CREATININE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES CONTROL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

AGED; BODY MASS INDEX; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; OXIDATIVE STRESS; REPRODUCIBILITY OF RESULTS; THIAZOLIDINEDIONES;

EID: 79955746931     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1174     Document Type: Article

References (26)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-1589.
3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545-2559.
4. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33(Suppl. 1): S11-S61.
5. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents. Diabetes Care 2008; 31(1): 20-25.
6. Hemkens LG, Grouven U, Bender R, et al.Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52(9): 1732-1744.
7. Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010; 33(9): 1997-2003.
8. Browker SL, Majundar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29(2): 254-258.
9. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52(9): 1766-1777.
10. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(6835): 813-820.
11. Hoeijmakers JHJ. DNA damage, aging and cancer. N Engl J Med 2009; 361(15): 1475-1485.
12. Code de la Santé Publique (2009) Partie législative. Première partie. Livre premier. Titre II, chapitre 1, Article L-1121-1. 18 Avril 2006 (version consolidée du 29 Août 2009). Available from [31 August 2009].
13. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycaemia in patients with type 2 diabetes. JAMA 2006; 295(14): 1681-1687.
14. Friedewald WT, Levy RI, Frederikson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. Clin Chem 1972; 18(6): 499-502.
15. Basu S. Metabolism of 8-isoprostaglandin F2alpha. FEBS Lett 1998; 428(1-2): 32-36.
16. Monnier L, Colette C, Mas E, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010; 53(3): 562-571.
17. Desideri G, Croce G, Tucci M, et al. Effects of bezafibrate and simvastatine on endothelial activation and lipid peroxidation on hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Endocrinol Metab 2003; 88(11): 5341-5347.
18. Goalstone M, Carel K, Leitner JW, Draznin B. Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-mitogen-activated protein kinase pathway. Endocrinology 1997; 138(12): 5119-5124.
19. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI3-kinase and MAP-kinase mediated signaling in human muscle. J Clin Invest 2000; 105(3): 311-320.
20. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes 2006; 55(8): 2392-2397.
21. DeFronzo R. From the triumvirat to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4): 773-795.
22. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997; 5(3): 177-269.
23. Ryysy L, Häkkinen A-M, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49(5): 749-758.
24. Riddle M, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 2003; 26(11): 3080-3086.
25. Holman RR, Farmer AJ, Davies MJ, et al.Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361(18): 1736-1747.
26. Draznin B. Mitogenic action of insulin: friend, foe or "frenemy"? Diabetologia 2010; 53(2): 229-233.